Compare LUMN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUMN | HALO |
|---|---|---|
| Founded | 1968 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 8.1B |
| IPO Year | 1994 | 2001 |
| Metric | LUMN | HALO |
|---|---|---|
| Price | $8.02 | $71.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $7.25 | ★ $78.64 |
| AVG Volume (30 Days) | ★ 12.9M | 1.7M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | ★ $12,402,000,000.00 | $151,862,000.00 |
| Revenue This Year | N/A | $28.24 |
| Revenue Next Year | N/A | $12.56 |
| P/E Ratio | ★ N/A | $58.32 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.37 | $51.06 |
| 52 Week High | $11.95 | $82.22 |
| Indicator | LUMN | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 57.48 |
| Support Level | $7.40 | $67.94 |
| Resistance Level | $8.42 | $71.38 |
| Average True Range (ATR) | 0.51 | 2.03 |
| MACD | -0.15 | -0.11 |
| Stochastic Oscillator | 18.61 | 79.32 |
Lumen Technologies is one of the largest telecommunications carriers serving global enterprises. The merger with Level 3 in 2017, the 2022 divestiture of much of its local phone business in rural areas, and the 2026 sale of its remaining consumer fiber network to AT&T have shifted the company's operations away from the legacy consumer business and toward enterprise services, which account for about 85%-90% of revenue. Lumen offers businesses a full suite of communications services, providing colocation and data center services, data transportation, phone service, and internet access.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.